



- (51) International Patent Classification:
A61K 39/12 (2006.01)
- (21) International Application Number:
PCT/US2021/045178
- (22) International Filing Date:
09 August 2021 (09.08.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/063,530 10 August 2020 (10.08.2020) US
- (71) Applicant: **THE SCRIPPS RESEARCH INSTITUTE**
[US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).
- (72) Inventors: **HE, Linling**; 4267 Robins Street, San Diego, CA 92122 (US). **ZHU, Jiang**; 4267 Robins Street, San Diego, CA 92122 (US). **CHAUDHARY, Anshul**; 8673 Via Mallorca, #53, La Jolla, CA 92037 (US). **WILSON, Ian**; 1025 Newkirk Drive, La Jolla, CA 92037 (US).
- (74) Agent: **FITTING, Thomas** et al.; The Scripps Research Institute, 10550 North Torrey Pines Road, Maildrop TPC-8, La Jolla, CA 92037 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS RELATED TO EBOLA VIRUSVACCINES




FIG. 1

(57) Abstract: The present invention provides novel engineered Ebolavirus GP proteins and polypeptides, as well as scaffolded vaccine compositions that display the engineered proteins. The invention also provides methods of using such engineered Ebolavirus GP proteins and vaccine compositions in various therapeutic applications, e.g., for preventing or treating Ebolavirus infections.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*